Oppenheimer Cuts Teladoc Health (NYSE:TDOC) Price Target to $7.00

Teladoc Health (NYSE:TDOC) had its price target cut by Oppenheimer from $12.00 to $7.00 in a report released on Tuesday,Benzinga reports. They currently have an outperform rating on the health services provider’s stock.

A number of other brokerages also recently issued reports on TDOC. TD Cowen dropped their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Thursday, February 26th. Canaccord Genuity Group lowered their target price on shares of Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Leerink Partners dropped their target price on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating for the company in a research report on Thursday, February 26th. Stifel Nicolaus cut their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.56.

Teladoc Health Stock Performance

NYSE TDOC opened at $5.13 on Tuesday. The company’s 50 day simple moving average is $5.82 and its two-hundred day simple moving average is $7.14. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.90. The stock has a market capitalization of $915.19 million, a PE ratio of -4.50 and a beta of 2.13.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm had revenue of $642.27 million for the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The business’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts predict that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after acquiring an additional 891,732 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Teladoc Health by 8.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after purchasing an additional 605,061 shares during the period. Geode Capital Management LLC lifted its position in Teladoc Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after purchasing an additional 18,394 shares during the last quarter. Jupiter Asset Management Ltd. boosted its stake in shares of Teladoc Health by 293.9% during the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares during the period. Finally, Nuveen LLC boosted its stake in shares of Teladoc Health by 38.7% during the fourth quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after purchasing an additional 742,240 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.